Would you consider exemestane (instead of fulvestrant) in post-menopausal patients with hormone receptor pos, HER2- breast cancer who progress on letrozole or anastrozole?
There is limited data that suggests steroidal AI exemestane could be of some benefit after nonsteroidal AI failure (Lonning PE et al. J Clin Oncol 2000; 18:2234-2244.)
Answer from: Medical Oncologist at Community Practice
Generally would not. I usually do Fulvestrant +/- CDK inhibitor if not received in the first line setting, as second line and reserve exemestane to afterwards combined with everolimus. If a patient has minimal disease progression on letrozole/anastrozole and really does not want a monthly injec...
Sign in or Register to read more